Sandbox carlos: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 2: Line 2:
:*'''Treatment'''<ref>{{citeweb|title=CDC Dientamoeba fragilis|url=http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html}}</ref><ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy 2014 | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2014 | isbn = 978-1930808782 }}</ref><ref>{{Cite journal| doi = 10.1016/j.ijpddr.2012.08.002| issn = 2211-3207| volume = 2| pages = 204–215| last1 = Nagata| first1 = Noriyuki| last2 = Marriott| first2 = Deborah| last3 = Harkness| first3 = John| last4 = Ellis| first4 = John T.| last5 = Stark| first5 = Damien| title = Current treatment options for Dientamoeba fragilis infections| journal = International Journal for Parasitology. Drugs and Drug Resistance| date = 2012-12| pmid = 24533282| pmc = PMC3862407}}</ref>
:*'''Treatment'''<ref>{{citeweb|title=CDC Dientamoeba fragilis|url=http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html}}</ref><ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy 2014 | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2014 | isbn = 978-1930808782 }}</ref><ref>{{Cite journal| doi = 10.1016/j.ijpddr.2012.08.002| issn = 2211-3207| volume = 2| pages = 204–215| last1 = Nagata| first1 = Noriyuki| last2 = Marriott| first2 = Deborah| last3 = Harkness| first3 = John| last4 = Ellis| first4 = John T.| last5 = Stark| first5 = Damien| title = Current treatment options for Dientamoeba fragilis infections| journal = International Journal for Parasitology. Drugs and Drug Resistance| date = 2012-12| pmid = 24533282| pmc = PMC3862407}}</ref>
::* 1. Preferred regimen: [[Iodoquinol]] 650 mg PO tid for 20 days
::* 1. Preferred regimen: [[Iodoquinol]] 650 mg PO tid for 20 days
:::* Note (1) Treatment in pregnancy: Iodoquinol use in pregnancy is limited, and risk to the embryo-fetus is unknown, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
:::* 1.1 '''Treatment in pregnancy'''
:::* Note (2) Treatment during lactation: Iodoquinol should be used with caution in breastfeeding women.
::::* Iodoquinol use in pregnancy is limited, and risk to the embryo-fetus is unknown, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
:::* Note (3) Treatment in pediatric patients: [[Iodoquinol]] 30–40 mg/kg/day (max: 2g) PO in 3 doses for 􏰄20 days. The safety of iodoquinol in children has not been established.
:::* 1.2 '''Treatment during lactation'''
::* 2. Alternative regimen: [[Tetracycline]] 500 mg PO qid for 10 days.
::::* Iodoquinol should be used with caution in breastfeeding women.
::* 3. Alternative regimen: [[Metronidazole]] 500–750 mg PO three times daily for 10 days {{or}} [[Tetracycline]] 500 mg PO qid for 10 days.
:::* 1.3 '''Treatment in pediatric patients'''
::::* [[Iodoquinol]] 30–40 mg/kg/day (max: 2g) PO in 3 doses for 􏰄20 days. The safety of iodoquinol in children has not been established.
 
::* 2. Alternative regimen (1): [[Tetracycline]] 500 mg PO qid for 10 days
:::* 2.1 '''Treatment in pediatric patients'''
::::* [[Tetracycline]] 40 mg/kg/day (max: 2 g) PO in 4 doses for􏰄 10 days
 
::* 3. Alternative regimen (2): [[Metronidazole]] 500–750 mg PO three times daily for 10 days {{or}} [[Tetracycline]] 500 mg PO qid for 10 days.
:::* Note (1) Treatment in pregnancy: Metronidazole is in pregnancy category B. Data on the use of this drug in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. May be used during pregnancy in those patients who will clearly benefit from the drug, although its use in the first trimester is generally not advised.
:::* Note (1) Treatment in pregnancy: Metronidazole is in pregnancy category B. Data on the use of this drug in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. May be used during pregnancy in those patients who will clearly benefit from the drug, although its use in the first trimester is generally not advised.
:::* Note (2) Treatment during lactation: Should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
:::* Note (2) Treatment during lactation: Should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
:::* Note (3) Treatment in pediatric patients: The safety in children has not been established, is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
:::* Note (3) Treatment in pediatric patients: The safety in children has not been established, is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
::* 4. Alternative regimen: [[Paromomycin]] 25–35 mg/kg per day PO in three divided doses for 7 days.
::* 4. Alternative regimen (3): [[Paromomycin]] 25–35 mg/kg per day PO in three divided doses for 7 days.
:::* Note (1) Treatment in pregnancy: Oral dose generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
:::* Note (1) Treatment in pregnancy: Oral dose generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
:::* Note (2) Treatment during lactation: Oral dose is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.
:::* Note (2) Treatment during lactation: Oral dose is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.

Revision as of 19:37, 17 July 2015

  • 1. Preferred regimen: Iodoquinol 650 mg PO tid for 20 days
  • 1.1 Treatment in pregnancy
  • Iodoquinol use in pregnancy is limited, and risk to the embryo-fetus is unknown, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • 1.2 Treatment during lactation
  • Iodoquinol should be used with caution in breastfeeding women.
  • 1.3 Treatment in pediatric patients
  • Iodoquinol 30–40 mg/kg/day (max: 2g) PO in 3 doses for 􏰄20 days. The safety of iodoquinol in children has not been established.
  • 2. Alternative regimen (1): Tetracycline 500 mg PO qid for 10 days
  • 2.1 Treatment in pediatric patients
  • Tetracycline 40 mg/kg/day (max: 2 g) PO in 4 doses for􏰄 10 days
  • 3. Alternative regimen (2): Metronidazole 500–750 mg PO three times daily for 10 days OR Tetracycline 500 mg PO qid for 10 days.
  • Note (1) Treatment in pregnancy: Metronidazole is in pregnancy category B. Data on the use of this drug in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. May be used during pregnancy in those patients who will clearly benefit from the drug, although its use in the first trimester is generally not advised.
  • Note (2) Treatment during lactation: Should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
  • Note (3) Treatment in pediatric patients: The safety in children has not been established, is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
  • 4. Alternative regimen (3): Paromomycin 25–35 mg/kg per day PO in three divided doses for 7 days.
  • Note (1) Treatment in pregnancy: Oral dose generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
  • Note (2) Treatment during lactation: Oral dose is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.
  • Note (3) Treatment in pediatric patients: The safety of oral dose in children has not been formally evaluated. However, the safety profiles likely are comparable in children and adults.


References

  1. ↑ Template:Citeweb
  2. ↑ Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
  3. ↑ Nagata, Noriyuki; Marriott, Deborah; Harkness, John; Ellis, John T.; Stark, Damien (2012-12). "Current treatment options for Dientamoeba fragilis infections". International Journal for Parasitology. Drugs and Drug Resistance. 2: 204–215. doi:10.1016/j.ijpddr.2012.08.002. ISSN 2211-3207. PMC 3862407. PMID 24533282. Check date values in: |date= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_carlos&oldid=1119479"